Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma
Authors:
- 4 June 2013
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 133 (9) , 2123-2132
Abstract
Synthetic lethal interactions in cancer hold the potential for successful combined therapies, which would avoid the difficulties of single molecule‐targeted treatment. Identification of interactions that are specific for human tumors is an open problem in cancer research. This work aims at deciphering synthetic sick or lethal interactions directly from somatic alteration, expression and survival data of cancer patients. To this end, we look for pairs of genes and their alterations or expression levels that are “avoided” by tumors and “beneficial” for patients. Thus, candidates for synthetic sickness or lethality (SSL) interaction are identified as such gene pairs whose combination of states is under‐represented in the data. Our main methodological contribution is a quantitative score that allows ranking of the candidate SSL interactions according to evidence found in patient survival. Applying this analysis to glioblastoma data, we collect 1,956 synthetic sick or lethal partners for 85 abundantly altered genes, most of which show extensive copy number variation across the patient cohort. We rediscover and interpret known interaction betweenTP53andPLK1, as well as provide insight into the mechanism behindEGFRinteracting withAKT2, but notAKT1norAKT3. Cox model analysis determines 274 of identified interactions as having significant impact on overall survival in glioblastoma, which is more informative than a standard survival predictor based on patient's age.Keywords
This publication has 42 references indexed in Scilit:
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Harnessing synthetic lethal interactions in anticancer drug discoveryNature Reviews Drug Discovery, 2011
- Genetic Interactions in Cancer Progression and TreatmentCell, 2011
- Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBMNeuro-Oncology, 2011
- Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomesNature Reviews Drug Discovery, 2011
- The Genetic Landscape of a CellScience, 2010
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular OncologyClinical Cancer Research, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005